{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:28:57Z","timestamp":1794508137672,"version":"4.9.1"},"reference-count":13,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"2021 Changzhou Key R&D Program","award":["20210464"],"award-info":[{"award-number":["20210464"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>Epilepsy patients exhibit considerable differences in their response to sodium valproate (VPA) therapy, a phenomenon that might be attributed to individual genetic variances. The role of genetic variations, specifically in sodium channels encoded by SCN1A and SCN2A genes, in influencing the effectiveness of VPA in treating epilepsy is still debated. This research focuses on examining the impact of these genetic polymorphisms on the efficacy of VPA therapy among pediatric epilepsy patients in China.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Five single nucleotide polymorphisms (SNPs), including SCN1A (rs10188577, rs2298771, rs3812718) and SCN2A (rs2304016, rs17183814), were genotyped in 233 epilepsy patients undergoing VPA therapy. The associations between genotypes and the antiepileptic effects of VPA were assessed, with 128 patients categorized as VPA responders and 105 as VPA non-responders.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>In the context of VPA monotherapy, SCN1A rs2298771 and SCN2A rs17183814 were found to be significantly associated with VPA response (<jats:italic>P<\/jats:italic>&lt; 0.05).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our study suggests the findings of this investigation indicate that the polymorphisms SCN1A rs2298771 and SCN2A rs17183814 could potentially act as predictive biomarkers for the responsiveness to VPA among Chinese epilepsy patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0304869","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T17:31:03Z","timestamp":1717608663000},"page":"e0304869","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of SCN1Aand SCN2A gene polymorphisms on the efficacy of valproic acid treatment in Chinese children with epilepsy"],"prefix":"10.1371","volume":"19","author":[{"given":"Zejun","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanzhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9607-6179","authenticated-orcid":true,"given":"Aibin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"issue":"3","key":"pone.0304869.ref001","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/pr.115.012021","article-title":"Epilepsy, Antiepileptic Drugs, and Aggression: an Evidence-Based Review","volume":"68","author":"MJ Brodie","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"1","key":"pone.0304869.ref002","first-page":"5","article-title":"Advances in the genomics of sodium valproate","volume":"38","author":"Zhou Xun","year":"2020","journal-title":"Journal of Pharmacy Practice"},{"issue":"52","key":"pone.0304869.ref003","doi-asserted-by":"crossref","first-page":"26549","DOI":"10.1073\/pnas.1909696116","article-title":"Valproic acid interactions with the NavMs voltage-gated sodium channel","volume":"116","author":"G Zanatta","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"pone.0304869.ref004","doi-asserted-by":"crossref","first-page":"e148370","DOI":"10.1172\/JCI148370","article-title":"Epilepsy channelopathies go neddy: stabilizing NaV1.1 channels by neddylation.","volume":"131","author":"SC Cannon","year":"2021","journal-title":"j Clin Invest"},{"key":"pone.0304869.ref005","doi-asserted-by":"crossref","first-page":"591828","DOI":"10.3389\/fneur.2020.591828","article-title":"Association Between SCN1A rs2298771, SCN1A rs10188577, SCN2A rs17183814, and SCN2A rs2304016 Polymorphisms and Responsiveness to Antiepileptic Drugs: a Meta-Analysis","volume":"11","author":"M Li","year":"2021","journal-title":"frontiers in neurology"},{"issue":"3","key":"pone.0304869.ref006","first-page":"S17","article-title":"SCN1A-related phenotypes: Epilepsy and beyond","volume":"60","author":"IE Scheffer","year":"2019","journal-title":"Epilepsia"},{"key":"pone.0304869.ref007","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejpn.2019.12.016","article-title":"The phenotypic spectrum of SCN2A-related epilepsy","volume":"24","author":"C Reynolds","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"pone.0304869.ref008","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41583-020-00418-4","article-title":"Sodium channelopathies in neurodevelopmental disorders","volume":"22","author":"MH Meisler","year":"2021","journal-title":"Nat Rev Neurosci"},{"key":"pone.0304869.ref009","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.dib.2018.08.122","article-title":"Data on mutations and Clinical features in SCN1A or SCN2A gene","volume":"22","author":"Y Kong","year":"2018","journal-title":"Data Brief"},{"key":"pone.0304869.ref010","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.2217\/pgs.12.127","article-title":"SCN1AIVS5N+5 polymorphism and response to sodium valproate: a multicenter study","volume":"13","author":"BS Haerian","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"12","key":"pone.0304869.ref011","first-page":"4","article-title":"Effect of SCN1A,SCN2A gene polymorphisms on the therapeutic efficacy of sodium valproate in epileptic children","volume":"26","author":"Shi Yanrong","year":"2020","journal-title":"Journal of Pediatric Pharmacy"},{"issue":"5","key":"pone.0304869.ref012","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00228-019-02633-0","article-title":"SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients","volume":"75","author":"L Shi","year":"2019","journal-title":"European Journal of Clinical Pharmacology"},{"key":"pone.0304869.ref013","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pediatrneurol.2023.06.010","article-title":"SCN1A Polymorphisms and Haplotypes Are Associated With Valproic Acid Treatment Outcomes in Chinese Children With Epilepsy","volume":"146","author":"J Zhu","year":"2023","journal-title":"Pediatr Neurol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T17:31:19Z","timestamp":1717608679000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304869"}},"subtitle":[],"editor":[{"given":"Vijayaprakash","family":"Suppiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":13,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0304869","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0304869.g001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0304869.g002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0304869.g003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0304869.g004","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0304869.g005","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0304869.g006","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0304869.g007","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0304869.t001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0304869.t002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0304869.t003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0304869.s001","asserted-by":"subject"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]}}}